CEACAM5 and breast cancer: The screening of circulating cytokeratins in BC patients at diagnosis is actually not recommended; however, recent observations showed that the detection rate of hepatic metastases in patients with BC can be raised up to 90% by simultaneous testing the serum levels of CA15-3, CEA, and circulating cytokeratins (TPA, TPS, and CYFRA 21.1) [45, 46].